Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC

BackgroundWhile neoadjuvant chemoimmunotherapy (NACI) improves outcomes in resectable non-small cell lung cancer (NSCLC), a significant subset of patients exhibits innate resistance. Biomarkers predicting response are urgently needed. Given the central role of antigen processing in immunotherapy eff...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ru Xie, Ke Zhai, Jinming Yu, Miaoqing Zhao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-09-01
Edice:	Frontiers in Immunology
Témata:	neoadjuvant immunotherapy combined with chemotherapy predictive markers NSCLC LMP2 PSME1 PSME2
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654573/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!